Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites

Gut

Volumn 59, Issue 1, 2010, Pages 105-110

  Krag, A ^a   Bendtsen, F ^a   Henriksen, J H ^a   Mooller S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FORWARD HEART FAILURE; FUNCTIONAL ASSESSMENT; HEPATORENAL SYNDROME; HUMAN; IMAGE ANALYSIS; KIDNEY FAILURE; LIVER CIRRHOSIS; MALE; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; SYSTOLE;

AGED; CARDIAC OUTPUT, LOW; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; RENAL CIRCULATION; SURVIVAL ANALYSIS;

EID: 73449112667     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.180570     Document Type: Article

References (39)

1. Gines P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-54.
2. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46:935-46.
3. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
4. Moøller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995;109:1917-25.
5. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-47.
6. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-8.
7. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8.
8. Liang KV, Williams AW, Greene EL, et al. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 2008;36:75-88.
9. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-76.
10. Flynn FV. Assessment of renal function: selected developments. Clin Biochem 1990;23:49-54.
11. 51Cr-EDTA provides a precise and convenient technique for measurement of glomerular filtration rate in diabetic humans. J Am Soc Nephrol 1996;7:118-27.
12. Gaspari F, Perico N, Remuzzi G. Measurement of glomerular filtration rate. Kidney Int 1997;63:151-4.
13. 131I-hippuran extraction in man: effects of dopamine. Br J Clin Pharmacol 2002;54:675-7.
14. Schlegel JU, Smith BG, O'Dell RM. Estimation of effective renal plasma flow using I-131-labeled hippuran. J Appl Physiol 1962;17:80-2.
15. Angeli P, De BE, Dalla PM, et al. Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention. Hepatology 1992;15:651-4.
16. Koomans HA, Boer WH, Dorhout Mees EJ. Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int 1989;36:2-12.
17. Thomsen K. Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 1984;37:217-23.
18. Sciagra R. The expanding role of left ventricular functional assessment using gated myocardial perfusion SPECT: the supporting actor is stealing the scene. Eur J Nucl Med Mol Imaging 2007;34:1107-22.
19. Abidov A, Germano G, Hachamovitch R, et al. Gated SPECT in assessment of regional and global left ventricular function: major tool of modern nuclear imaging. J Nucl Cardiol 2006;13:261-79.
20. Hesse B, Tagil K, Cuocolo A, et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging 2005;32:855-97.
21. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863- 71.
22. Henriksen JH, Fuglsang S, Bendtsen F, et al. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002;36:513-20.
23. Kubo SH, Walter BA, John DH, et al. Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch Intern Med 1987;147:1227-30.
24. Jegier W, Sekelj P, Auld PA, et al. The relation between cardiac output and body size. Br Heart J 1963;25:425-30.
25. Neubauer S. The failing heart - an engine out of fuel. N Engl J Med 2007;356:1140-51.
26. Milani A, Zaccaria R, Bombardieri G, et al. Cirrhotic cardiomyopathy. Dig Liver Dis 2007;39:507-15.
27. Henriksen JH, Gotze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-7.
28. Moøller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
29. Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005;26:11-7.
30. McAlister FA, Ezekowitz J, Tonelli M, et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004-9.
31. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006;17:1820-32.
32. Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean? J Am Soc Nephrol 2007;18:2028-31.
33. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9.
34. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-10.
35. Brinch K, Moller S, Bendtsen F, et al. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003;39:24-31.
36. Krag A, Moøller S, Henriksen JH, et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007;46:1863-71.
37. Moøller S, Hansen EF, Becker U, et al. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000;20:51-9.
38. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505.
39. Bosch J, Berzigotti A, Garcia-Pagan JC, et al. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008;48:68-92.